Clinician’s Guide to Cardio-Oncology: Best Practice and Future Directions

Hosted by the Washington University and Barnes-Jewish Heart & Vascular Center, “Clinician’s Guide to Cardio-Oncology: Best Practice and Future Directions” was presented on November 10, 2018 in Chicago, Illinois. This event was not part of the official Scientific Sessions 2018 as planned by the AHA committee on Scientific Sessions Program.

Presentation topics included monitoring and managing vascular toxicity, leveraging big data and the EHR to better inform cardio-oncology, comprehensive cardiac MRI safety, the utility for Echo/Global Longitudinal strain in cardiotoxicity, and the treatment of Amyloidosis.


Leveraging Big Data and the EHR to Better Inform the Practice of Cardio-Oncology

Washington University cardiologist at Barnes-Jewish Hospital, Joshua Mitchell, MD, discusses the continually expanding field of available cancer therapies.
Joshua Mitchell, MD

Joshua Mitchell, MD

Assistant Professor of Medicine Director,
Cardio-Oncology Fellowship,
Washington University School of Medicine
St. Louis, MO

What are the Best Approaches to Monitor and Manage Vascular Toxicity in Cardio-Oncology?

Mayo Clinic cardiologist, Joerg Herrmann, MD, provides a review of the three main types of presentation of vascular toxicity seen with chemotherapy: acute vasospasm, acute thrombosis, and accelerated atherosclerosis.
Joerg Herrmann, MD

Joerg Herrmann, MD

Director, Cardio-Oncology Clinic
Mayo Clinic, Rochester, MN

Comprehensive Cardiac MRI Therapy is a Must for Cardiac Safety

Washington University radiologist, Pamela Woodard, MD, presents an overview and update on how cardiac MRI can provide cardiac assessment and management of patients undergoing chemotherapy.
Pamela Woodard, MD

Pamela Woodard, MD

Professor of Radiology,
Washington University School of Medicine
St. Louis, MO

The Utility and Future for Strain Imaging in Cardio-Oncology

Washington University cardiologist, John Gorcsan, MD, discusses how echocardiographic strain imaging has emerged as an important noninvasive tool to assist in monitoring for chemotherapy cardiotoxicity.
John Gorcsan, MD

John Gorcsan, MD

Professor of Medicine,
Director of Clinical Research,
Washington University School of Medicine
St. Louis, MO

Current Treatment and Future Developments in the Treatment of Amyloidosis

Washington University cardiologist at Barnes-Jewish Hospital, Daniel Lenihan, MD, presents a contemporary update of the diagnosis, epidemiology and current treatment available for cardiac amyloidosis.
Daniel Lenihan, MD

Daniel Lenihan, MD

Professor of Medicine
Director, Cardio-Oncology Center of Excellence,
Washington University School of Medicine
St. Louis, MO